natgillin/translations-raw huggingface dataset:
Indinavir og ritonavir hæmmer CYP3A4 og som følge heraf forventes de at øge carbamazepins plasmakoncentration.
Interaction with indinavir/ ritonavir not studied Indinavir and ritonavir inhibit CYP3A4 and as a result are expected to increase the plasma concentrations of carbamazepine.
Omhyggelig monitorering af terapeutiske virkninger og bivirkninger anbefales, når carbamazepin administreres samtidigt med indinavir/ ritonavir.
Careful monitoring of therapeutic and adverse effects is recommended when carbamazepine is concomitantly administered with indinavir/ ritonavir.
Divalproex, lamotrigin, phenytoin ANTIDEPRESSIVA
Divalproex, lamotrigine, phenytoin ANTIDEPRESSANTS
Ritonavir inducerer oxidering ved CYP2C9 samt glucuronidering og som følge heraf forventes det at reducere plasmakoncentrationen af antikonvulsiva.
Interaction with indinavir/ ritonavir not studied Ritonavir induces oxidation by CYP2C9 and glucuronidation and as a result is expected to decrease the plasma concentrations of anticonvulsants.
Omhyggelig monitorering af serumkoncentrationen eller den terapeutiske virkning, når disse lægemidler administreres samtidigt med indinavir/ ritonavir.
Careful monitoring of serum levels or therapeutic effects is recommended when these medicines are concomitantly administered with indinavir/ ritonavir.
Trazodon 50 mg SD Ritonavir 200 mg BID ANTIHISTAMINER
Trazodone 50 mg SD Ritonavir 200 mg BID ANTIHISTAMINES
Trazodon AUC: ↑ 2, 4 gange.
Interaction with indinavir/ ritonavir not studied Trazodone AUC:
En stigning i incidensen af trazodonrelaterede bivirkninger blev observeret, når dette blev administreret samtidigt med ritonavir.
2.4-fold An increase in the incidence in trazodone- related adverse events was noted when coadministered with ritonavir.
Kombinationen af trazodon og indinavir/ ritonavir bør anvendes med forsigtighed ved at initiere behandling med trazodon i laveste dosering og monitorere mht. klinisk respons og tolerabilitet.
The combination of trazodone with indinavir/ ritonavir should be used with caution, initiating trazodone at the lowest dosage and monitoring for clinical response and tolerability.
Ritonavir kan modificere P - glycoproteinmedieret fexofenadinefflux, når det ved samtidig administration medfører øget koncentration af fexofenadin.
Interaction with indinavir/ ritonavir not studied Ritonavir may modify P-glycoprotein mediated fexofenadine efflux when coadministered resulting in increased concentrations of fexofenadine.
Omhyggelig monitorering af terapeutiske virkninger og bivirkninger anbefales, når fexofenadin administreres samtidigt med indinavir/ ritonavir.
Careful monitoring of therapeutic and adverse effects is recommended when fexofenadine is concomitantly administered with indinavir/ ritonavir.
Loratidin CALCIUMKANALBLOKKERE
Loratidine CALCIUM CHANNEL BLOCKERS
Indinavir og ritonavir hæmmer CYP3A4 og som følge heraf forventes de at øge loratidins plasmakoncentration.
Interaction with indinavir/ ritonavir not studied Indinavir and ritonavir inhibit CYP3A4 and as a result are expected to increase the plasma concentrations of loratidine.
Omhyggelig monitorering af terapeutiske virkninger og bivirkninger anbefales, når loratidin administreres samtidigt med indinavir/ ritonavir.
Careful monitoring of therapeutic and adverse effects is recommended when loratidine is concomitantly administered with indinavir/ ritonavir.
Dilitazem 120 mg QD (Indinavir/ ritonavir 800/ 100 BID Amlodipin 5 mg QD (Indinavir/ ritonavir 800/ 100 BID)
Dilitazem 120 mg QD (Indinavir/ ritonavir 800/ 100 BID)
Dilitazem AUC0- 24t: ↑ 43%.
43% Indinavir/ ritonavir AUCs: ↔
Indinavir/ ritonavir AUC: ↔ Amlodipin AUC0- 24t: ↑ 80% Indinavir/ ritonavir AUC: ↔
80% Indinavir/ ritonavir AUCs: ↔
Dosismodificering af calciumkanalblokkere bør overvejes, når de administreres samtidigt med indinavir/ ritonavir, da det kan medføre øget respons.
administered with indinavir/ ritonavir as it may result in an increased response.
15 Lægemidler i henhold til Interaktion terapeutisk område HMG- CoA- REDUKTASEHÆMMERE IMMUNOSUPPRESSIVA
15 Medicinal products by Interaction therapeutic areas HMG-CoA REDUCTASE INHIBITORS IMMUNOSUPPRESSIVES
Rekommandationer vedr. samtidig administration Samme anbefalinger som for indinavir uden ritonavir - boosting (se tabel 1).
Recommendations concerning co-administration Same recommendations as for indinavir without ritonavir boosting (see Table 1).
Cyclosporin A Efter initiering af behandling med (Indinavir/ ritonavir 800/ 100 indinavir/ ritonavir 800/ 100 BID eller BID) lopinavir/ ritonavir 400/ 100 BID var det nødvendigt med dosisreduktion af cyclosporin A til 5- 20% af tidligere dosis for at opretholde cyclosporin A - koncentrationen inden for det terapeutiske område i én undersøgelse.
Cyclosporine A Following initiation of indinavir/ ritonavir (Indinavir/ ritonavir 800/ 100 800/ 100 BID or lopinavir/ ritonavir 400/ 100 BID) BID, dose reduction of cyclosporine A to 5- 20% of prior dose was needed to maintain cyclosporine A levels within therapeutic range in one study.
Dosisjustering af Cyclosporin A bør foretages i henhold til den lavest målte cyclosporin A koncentration i blodet.
Cyclosporine A dose adjustments should be made according to measured cyclosporine A trough blood levels.
Indinavir og ritonavir hæmmer CYP3A4 og som følge heraf forventes de at øge tacrolimus 'plasmakoncentration.
PDE5 INHIBITOR
Omhyggelig monitorering af terapeutisk virkning og bivirkninger anbefales, når tacrolimus administreres samtidigt med indinavir/ ritonavir.
Careful monitoring of therapeutic and adverse effects is recommended when tacrolimus is concomitantly administered with indinavir/ ritonavir.
Sildenafil, tadalafil Interaktion er ikke undersøgt.
Sildenafil, tadalafil Interaction not studied.
For sildenafil og tadalafil gælder de samme anbefalinger som for indinavir uden ritonavir - boosting (se tabel 1).
For sildenafil and tadalafil, same recommendations as for indinavir without ritonavir boosting (see Table 1).
Vardenafil Interaktion er ikke undersøgt.
SEDATIVES/ HYPNOTICS
2, 5 mg over en 72- timers periode, når det gives sammen med en boostet proteasehæmmer.
Vardenafil dose should not exceed a maximum of 2.5 mg in a 72-hour period when given with a boosted protease inhibitor.
Indinavir og ritonavir hæmmer CYP3A4 og som følge heraf forventes de at øge buspirons plasmakoncentration.
Buspirone Interaction with indinavir/ ritonavir not studied Indinavir and ritonavir inhibit CYP3A4 and as a result are expected to increase the plasma concentrations of buspirone.
Omhyggelig monitorering af terapeutisk virkning og bivirkninger anbefales, når buspiron administreres samtidigt med indinavir/ ritonavir.
Careful monitoring of therapeutic and adverse effects is recommended when buspirone is concomitantly administered with indinavir/ ritonavir.
Kombineret administration, som endnu ikke er undersøgt, forventes at øge koncentrationen af midazolam signifikant, især når midazolam gives peroralt (CYP3A4- hæmning).
STEROIDS
4. 3).
CRIXIVAN with ritonavir and oral midazolam should not be coadministered (see section 4.3).
Hvis CRIXIVAN og ritonavir administreres samtidigt med parenteral midazolam, bør det gøres på en intensivafdeling med tæt klinisk monitorering i tilfælde af respirationsdepression og/ eller forlænget sedering.
If CRIXIVAN with ritonavir is coadministered with parenteral midazolam, it should be done in an intensive care unit with close clinical monitoring in case of respiratory depression and/ or prolonged sedation.
Interaktion med indinavir/ ritonavir er ikke undersøgt. ↑ dexamethasoneksponering forventes (CYP3A- hæmning). ↓ indinavirs plasmakoncentrationer kan forventes (CYP3A- induktion).
Dexamethasone Interaction with indinavir/ ritonavir not studied ↑ dexamethasone exposure expected (CYP3A inhibition). ↓ indinavir plasma concentrations may be expected (CYP3A induction).
Omhyggelig monitorering af terapeutisk virkning og bivirkninger anbefales, når dexamethason administreres samtidigt med indinavir/ ritonavir.
Careful monitoring of therapeutic and adverse effects is recommended when dexamethasone is concomitantly administered with indinavir/ ritonavir.
For information om effekt af diæt eller mad på indinavirabsorption (se pkt.
For information regarding diet or the effect of food on indinavir absorption (see
4. 2 og 5. 2).
section 4.2 and 5.2).
Anvendelse under graviditet Der findes ikke tilstrækkelige og velkontrollerede undersøgelser hos gravide patienter.
Use during pregnancy There are no adequate and well-controlled studies in pregnant patients.
5. 2)
Given that substantially lower antepartum exposures have been observed in a small study of HIV-infected pregnant patients and the limited data in this patient population, indinavir use is not recommended in HIV-infected pregnant patients (see section 5.2).
Hyperbilirubinæmi, fortrinsvis rapporteret som forhøjet indirekte bilirubin, er observeret hos 14% af patienterne under behandling med indinavir.
Hyperbilirubinaemia, reported predominantly as elevated indirect bilirubin, has occurred in 14% of patients during treatment with indinavir.
4. 8).
Because it is unknown whether indinavir will exacerbate physiologic hyperbilirubinaemia in neonates, careful consideration must be given to the use of indinavir in pregnant women at the time of delivery (see section 4.8).
Anvendelse under amning Det anbefales at HIV- smittede kvinder, for at undgå overførsel af HIV, ikke under nogen omstændigheder ammer deres børn.
Use during lactation It is recommended that HIV− infected women do not breast− feed their infants under any circumstances in order to avoid transmission of HIV.
Det er uvist, om indinavir udskilles i modermælk.
It is not known whether indinavir is excreted in human milk.
Mødre bør instrueres i at ophøre med amning under behandling.
Mothers should be instructed to discontinue breast− feeding during treatment.
2. 000 patienter, af hvilke hovedparten var voksne mænd af europæisk afstamning (15% kvinder).
In controlled clinical trials conducted world– wide, indinavir was administered alone or in combination with other antiretroviral agents (zidovudine, didanosine, stavudine, and/ or lamivudine) to approximately 2,000 patients, the majority of whom were adult Caucasian males (15% females).
Mange af disse bivirkninger blev også fundet
Clinical adverse reactions reported by the investigators as possibly, probably, or definitely related to CRIXIVAN in ≥ 5% of patients treated with CRIXIVAN alone or in combination (n = 309) for 24 weeks are listed below.
17 almindeligt eller hyppigt forekommende tilstande i denne befolkningsgruppe.
Many of these adverse reactions were also identified as common pre– existing or frequently occurring medical conditions in this population.
Disse bivirkninger var: kvalme (35, 3%), hovedpine (25, 2%), diarré (24, 6%), asteni/ træthed (24, 3%), udslæt (19, 1%), smagsforstyrrelse (19, 1%), tør hud (16, 2%), abdominal smerte (14, 6%), opkastning (11, 0%), svimmelhed (10, 7%).
These adverse reactions were: nausea (35.3%), headache (25.2%), diarrhoea (24.6%), asthenia/ fatigue (24.3%), rash (19.1%), taste perversion (19.1%), dry skin (16.2%), abdominal pain (14.6%), vomiting (11.0%), dizziness (10.7%).
Med undtagelse af tør hud, udslæt og smagsforstyrrelser var forekomsten af bivirkninger den samme, eller højere, hos patienter i antiretroviral nukleosidanalog kontrolgruppen end hos patienter behandlet med CRIXIVAN alene eller i kombinationsbehandling.
With the exception of dry skin, rash, and taste perversion, the incidence of clinical adverse reactions was similar or higher among patients treated with antiretroviral nucleoside analogue controls than among patients treated with CRIXIVAN alone or in combination.
Denne overordnede sikkerhedsprofil forblev ens for 107 patienter behandlet med CRIXIVAN alene eller i kombinationsbehandling i op til 48 uger.
This overall safety profile remained similar for 107 patients treated with CRIXIVAN alone or in combination for up to 48 weeks.
Bivirkninger, inklusiv nefrolitiasis, kan medføre behov for seponering.
Adverse reactions, including nephrolithiasis, may lead to treatment interruption.
Der er også rapporteret bivirkninger efter markedsføring *, men da de stammer fra spontane rapporter kan hyppigheden ikke fastsættes.
Adverse reactions have also been reported during post-marketing experience* as they are derived from spontaneous reports, incidences cannot be determined.
Følgende bivirkninger er rapporteret for CRIXIVAN under kliniske undersøgelser og/ eller efter markedsføring.
17 The following adverse reactions have been reported during clinical studies and/ or post-marketing use for CRIXIVAN.
Meget almindelige (≥ 1/ 10); Almindelige (≥1/ 100, < 1/ 10); Ikke almindelige (≥ 1/ 1000, < 1/ 100); Sjældne (≥ 1/ 10, 000, < 1/ 1000); Meget sjældne (< 1/ 10, 000); Ikke kendt (kan ikke estimeres ud fra tilgængelige data).
Very common (≥ 1/ 10); Common (≥ 1/ 100, < 1/ 10); Uncommon (≥ 1/ 1,000, < 1/ 100); Rare (≥ 1/ 10,000, < 1/ 1,000); Very rare (< 1/ 10,000); not known (cannot be estimated from the available data).
Blod - og lymfesystem:
Blood and the lymphatic disorders:
4. 4).
Not known*: increased spontaneous bleeding in patients with haemophilia; anemia including acute haemolytic anaemia; thrombocytopenia (see section 4.4).
Anafylaktiske reaktioner.
Not known*: anaphylactoid reactions.
Ikke kendt *:
Metabolism and nutrition disorders:
4. 4).
Not known*: new onset diabetes mellitus or hyperglycaemia, or exacerbation of pre-existing diabetes mellitus (see section 4.4).
Oral paræstesi.
Very common: headache, dizziness Common: insomnia; hypoaesthesia; paraesthesia Not known*: oral paraesthesia.
Almindelige:
Gastrointestinal disorders:
Hepatitis inklusive rapporter om leversvigt; pancreatitis.
Very common: nausea; vomiting; diarrhoea; dyspepsia Common: flatulence; dry mouth; acid regurgitation Not known*: hepatitis, including reports of hepatic failure; pancreatitis.
Meget almindelige:
Skin and subcutaneous tissue disorders:
Udslæt inklusive erythema multiforme og Stevens- Johnsons syndrom; hypersensitiv vasculitis; alopeci, hyperpigmentering; urticaria; nedgroede tånegle og/ eller paronychia.
Very common: rash, dry skin Common: pruritus Not known*: rash including erythema multiforme and Stevens Johnson syndrome; hypersensitivity vasculitis; alopecia, hyperpigmentation; urticaria; ingrown toenails and/ or paronychia
Almindelig:
Musculoskeletal, connective tissue and bone disorders:
Myositis; rhabdomyolyse.
Common: myalgia Not known*: myositis; rhabdomyolysis
Meget almindelige:
Renal and urinary disorders:
Nefrolitiasis hos pædiatriske patienter i alderen 3 år og ældre.
Very common: nephrolithiasis in paediatric patients 3 years of age and older.
Nefrolitiasis hos voksne; dysuri.
Common: nephrolithiasis in adults; dysuria.
Generelt var disse bivirkninger
Nephrolithiasis, including flank pain with or without haematuria (including microscopic haematuria), has been reported in approximately 10% (252/ 2,577) of patients receiving CRIXIVAN in clinical trials at the recommended dose compared to 2.2% in the control arms.
1- 3 dage).
In general, these events were not associated with renal dysfunction and resolved with hydration and temporary interruption of therapy (e. g., 1– 3 days).
I kliniske undersøgelser af pædiatriske patienter i alderen 3 år og ældre svarede bivirkningsprofilen til den for voksne patienter, bortset fra en 29% højere frekvens af nefrolitiasis (20/ 70) hos pædiatriske patienter, som blev behandlet med CRIXIVAN ved den anbefalede dosis på 500 mg/ m2 hver 8. time.
In clinical trials in paediatric patients 3 years of age and older, the adverse experience profile was similar to that for adult patients except for a higher frequency of nephrolithiasis of 29% (20/ 70) in paediatric patients who were treated with CRIXIVAN at the recommended dose of 500 mg/ m2 every 8 hours.
Nefrolitiasis, i nogle tilfælde med nyreinsufficiens eller akut nyresvigt; pyelonefritis; interstitiel nefritis, i nogle tilfælde associeret med krystalaflejringer af indinavir.
Not known*: nephrolithiasis, in some cases with renal insufficiency or acute renal failure; pyelonephritis; interstitial nephritis, sometimes associated with indinavir crystal deposits.
4. 4).
In some patients, resolution of the interstitial nephritis did not occur following discontinuation of indinavir therapy; renal insufficiency; renal failure; leucocyturia (see section 4.4).
Almene symptomer og reaktioner på administrationsstedet:
18 General disorders and administration site conditions:
Asteni/ træthed; smagsforstyrrelser, mavesmerter.
Very common: asthenia/ fatigue; taste perversion; abdominal pain.
Ikke kendt *:
Not known*:
Antiretroviral kombinationsbehandling hos patienter med HIV associeret med omfordeling af kropsfedt (lipodystrofi), herunder tab af subkutant fedt perifert og i ansigtet, øget intraabdominalt og visceralt fedt, brysthypertrofi og dorsocervical fedtakkumulering (tyrenakke).
Combination antiretroviral therapy has been associated with redistribution of body fat (lipodystrophy) in HIV patients, including the loss of peripheral and facial subcutaneous fat, increased intra-abdominal fat and visceral fat, breast hypertrophy and dorsocervical fat accumulation (buffalo hump).
4. 4).
Combination antiretroviral therapy has been associated with metabolic abnormalities such as hypertriglyceridaemia, hypercholesterolaemia, insulin resistance, hyperglycaemia and hyperlactataemia (see section 4.4).
Fund ved laboratorieundersøgelser De laboratorieabnormiteter, der blev rapporteret af investigatorerne som muligvis, sandsynligvis eller klart relateret til CRIXIVAN hos ≥ 10% af de patienter, der er behandlet med CRIXIVAN alene eller i kombination, var følgende:
Laboratory test findings The laboratory abnormalities reported by the investigators as possibly, probably, or definitely related to CRIXIVAN in ≥ 10% of patients treated with CRIXIVAN alone or in combination were:
Meget almindelige (> 10%) Blod - og lymfesystem:
Very common (> 10%)
Nyrer og urinveje:
Blood and lymphatic system disorders: increases in MCV, decreases in neutrophils.
Lever og galdeveje:
Renal and urinary disorders: haematuria, proteinuria, crystalluria; pyuria in paediatric patients 3 years of age and older.
14% af de patienter, der er behandlet med CRIXIVAN alene eller i kombination med andre antiretrovirale stoffer, er der set isoleret, asymptomatisk hyperbilirubinæmi (totalbilirubin ≥2, 5 mg/ dl, 43 µmol/ l), der overvejende er indberettet som forhøjet indirekte bilirubin og sjældent associeret med stigninger i ALAT, ASAT eller alkalisk phosphatase.
Hepato-biliary disorders: isolated asymptomatic hyperbilirubinaemia (total bilirubin ≥ 2.5 mg/ dl, 43 mcmol/ l), reported predominantly as elevated indirect bilirubin and rarely associated with elevations in ALT, AST, or alkaline phosphatase, has occurred in approximately 14% of patients treated with CRIXIVAN alone or in combination with other antiretroviral agents.
De fleste patienter fortsatte behandlingen med CRIXIVAN uden dosisreduktion, og bilirubinværdierne faldt gradvist mod basisværdi.
Most patients continued treatment with CRIXIVAN without dosage reduction and bilirubin values gradually declined toward baseline.
Der opstod hyppigere hyperbilirubinæmi ved doser over 2, 4 g dagligt sammenlignet med doser under 2, 4 g dagligt.
Hyperbilirubinaemia occurred more frequently at doses exceeding 2.4 g/ day compared to doses less than 2.4 g/ day.
Forhøjet ALAT og ASAT.
Increased ALT and AST.
I kliniske undersøgelser med CRIXIVAN til pædiatriske patienter i alderen 3 år og ældre blev der konstateret asymptomatisk pyuri af ukendt ætiologi hos 10, 9% (6/ 55) af de patienter, der fik den anbefalede dosis CRIXIVAN på 500 mg/ m2 hver 8. time.
In clinical trials with CRIXIVAN in paediatric patients 3 years of age and older, asymptomatic pyuria of unknown etiology was noted in 10.9% (6/ 55) of patients who received CRIXIVAN at the recommended dose of 500 mg/ m2 every 8 hours.
Nogle af disse bivirkninger var associeret med en let stigning i serumkreatinin.
Some of these events were associated with mild elevation of serum creatinine.
Følgende yderligere laboratorieabnormiteter er rapporteret efter markedsføring; disse stammer fra spontane rapporter, for hvilke præcis hyppighedsforekomst ikke kan fastsættes:
The following additional laboratory abnormalities have been reported during post-marketing experience; they are derived from spontaneous reports for which precise incidences cannot be determined:
Metabolisme og ernæring:
Hepato-biliary disorders: liver function abnormalities.
Forhøjede serumtriglycerider, forhøjet serumkolesterol.
Musculoskeletal and connective tissue and bone disorders: increased CPK.
Lever og galdeveje:
4.9 Overdose
Leverfunktionsabnormiteter.
There have been reports of human overdose with CRIXIVAN.
Knogler, led, muskler og bindevæv:
The most commonly reported symptoms were gastro-intestinal (e. g., nausea, vomiting, diarrhoea) and renal (e. g., nephrolithiasis, flank pain, haematuria).
Øget kreatinfosfokinase.
It is not known whether indinavir is dialyzable by peritoneal or haemodialysis.
19 4. 9 Overdosering
19 5.
J05AE02
Protease inhibitor, ATC code JO5AE02
10 gange selektivitet for HIV- 1 i forhold til HIV- 2 proteinase.
Mechanism of action Indinavir inhibits recombinant HIV– 1 and HIV– 2 protease with an approximate tenfold selectivity for HIV– 1 over HIV– 2 proteinase.
Indinavir bindes reversibelt til det proteaseaktive site, hæmmer kompetitivt enzymet og forebygger derved den spaltning af det virale precursor polyprotein, som sker under modning af det nydannede, virale partikel.
Indinavir binds reversibly to the protease active site and inhibits competitively the enzyme, thereby preventing cleavage of the viral precursor polyproteins that occurs during maturation of the newly formed viral particle.
De derfor umodne partikler er non- infektiøse og ude af stand til at etablere nye infektionscykler.
The resulting immature particles are non– infectious and are incapable of establishing new cycles of infection.
Mikrobiologi Indinavir medierede i koncentrationer på 50- 100 nM 95% hæmning (IC95) af viral spredning (i forhold til en ubehandlet virusinficeret kontrol) i humane T- lymfocytcellekulturer og primære humane monocytter/ makrofager inficeret med henholdsvis HIV- 1 varianterne LAI, MN, RF og en makrofagtrofisk variant SF- 162.
Microbiology Indinavir at concentrations of 50 to 100 nM mediated 95% inhibition (IC95) of viral spread (relative to an untreated virus– infected control) in human T– lymphoid cell cultures and primary human monocytes/ macrophages infected with HIV− 1 variants LAI, MN, RF, and a macrophage– tropic variant SF– 162, respectively.
Indinavir i koncentrationer på 25- 100 nM medierede 95% hæmning af viral spredning i kulturer af mitogenaktiverede blodmononukleare celler fra perifert blod inficeret med forskellige, primære kliniske isolater af HIV- 1, inklusive isolater som var resistente over for zidovudin, samt non- nukleosid revers transcriptasehæmmere.
Indinavir at concentrations of 25 to 100 nM mediated 95% inhibition of viral spread in cultures of mitogen– activated human peripheral blood mononuclear cells infected with diverse, primary clinical isolates of HIV− 1, including isolates resistant to zidovudine and non– nucleoside reverse transcriptase inhibitors (NNRTIs).
Der sås synergistisk antiretroviral aktivitet, når humane T- lymfeceller inficerede med LAI varianten af HIV- 1 blev inkuberet med indinavir og enten zidovudin, didanosin eller en non- nukleosid revers transcriptasehæmmer.
Synergistic antiretroviral activity was observed when human T– lymphoid cells infected with the LAI variant of HIV– 1 were incubated with indinavir and either zidovudine, didanosine, or NNRTIs.
Lægemiddelresistens Nedsat suppression af virus- RNA forekom hos nogle patienter; CD4- celletallet holdt sig imidlertid ofte over niveauet fra før behandlingen.
Drug resistance Loss of suppression of viral RNA levels occurred in some patients; however, CD4 cell counts were often sustained above pre– treatment levels.